Skip to main content
SpringerLink
Log in

Matrix M Adjuvant Technology

  • Chapter
  • First Online:
Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines

Abstract

Vaccine adjuvants are substances or procedures that when added to or applied in vaccines aim at substantial improvement of the quality and/or magnitude of immune responses to the vaccine antigens. The term “adjuvant” is derived from the Latin term adjuvare, which means “to help.” The resulting immunological benefit of adjuvant addition depends not only on what kind of help the adjuvant can offer but also on what kind of help that is applicable to the antigen in question.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Brunner R, Jensen-Jarolim E, Pali-Schöll I (2010) The ABC of clinical and experimental adjuvants—a brief overview. Immunol Lett 128:29–35

    Article  PubMed  CAS  Google Scholar 

  2. Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10:787–796

    Article  PubMed  CAS  Google Scholar 

  3. Cox J, Coulter A (1997) Adjuvants—a classification and review of their modes of action. Vaccine 15:248–256

    Article  PubMed  CAS  Google Scholar 

  4. Rajput ZI, Hu S, Xiao C, Arijo AG (2007) Adjuvant effects of saponins on animal immune responses. J Zhejiang Univ Sci B 8:153–161

    Article  PubMed  CAS  Google Scholar 

  5. Francis G, Kerem Z, Makkar HP, Becker K (2002) The biological action of saponins in animal systems: a review. Br J Nutr 88:587–605

    Article  PubMed  CAS  Google Scholar 

  6. Kensil CR (1996) Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 13:1–55

    PubMed  CAS  Google Scholar 

  7. Waite DC, Jacobson EW, Ennis FA, Edelman R, White B, Kammer R, Anderson C, Kensil CR (2001) Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 19:3957–3967

    Article  PubMed  CAS  Google Scholar 

  8. Morein B, Sundquist B, Höglund S, Dalsgaard K, Osterhaus A (1984) Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308:457–460

    Article  PubMed  CAS  Google Scholar 

  9. Morein B, Sharp M, Sundquist B, Simons K (1983) Protein subunit vaccines of parainfluenza type 3 virus: immunogenic effect in lambs and mice. J Gen Virol 64:1557–1569

    Article  PubMed  CAS  Google Scholar 

  10. Özel M, Höglund S, Gelderblom H, Morein B (1989) Quarternary structure of the innubénostimulating complex (ISCOM). J Ultrastruct Mol Struct Res 102:240–248

    Article  PubMed  Google Scholar 

  11. Barr IG, Mitchell GF (1996) ISCOMs (immunostimulating complexes): the first decade. Immunol Cell Biol 74:8–25

    Article  PubMed  CAS  Google Scholar 

  12. Morein B, Lövgren-Bengtsson K (1998) Functional aspects of ISCOMs. Immunol Cell Biol 176:295–299

    Article  Google Scholar 

  13. Morein B, Lövgren-Bengtsson K (1999) Immunomodulation by ISCOMs. In: Boraschi D, Tagliabue A (eds) A companion to methods in enzymology. Developments in adjuvant technology. Methods 19:94–102

    Google Scholar 

  14. Sanders MT, Brown LE, Deliyannis G, Pearse MJ (2005) ISCOM-based vaccines: the second decade. Immunol Cell Biol 83:119–128

    Article  PubMed  CAS  Google Scholar 

  15. Jones PD, Tha Hla R, Morein B, Lövgren K, Ada GL (1988) Cellular immune responses in the murine lung to local immunization with influenza a virus glycoproteins in micelles and immunostimulating complexes (ISCOMs). Scand J Immunol 27:645–652

    Article  PubMed  CAS  Google Scholar 

  16. Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky J (1990) Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope proteins in ISCOMs. Nature 344:873–875

    Article  PubMed  CAS  Google Scholar 

  17. Wood JM (2001) Developing vaccines against pandemic influenza. Philos Trans R Soc Lond Biol Sci 356:1953–1960

    Article  CAS  Google Scholar 

  18. Daems R, Del Giudice G, Rappuoli R (2005) Anticipating crisis: towards a pandemic flu vaccination strategy through alignment of public health and industrial policy. Vaccine 23:5732–5742

    Article  PubMed  Google Scholar 

  19. Lövgren K, Morein B (1991) The ISCOM: an antigen delivery system with built-in adjuvant. Mol Immunol 28:285–286

    Article  PubMed  Google Scholar 

  20. Fossum C, Bergström M, Lövgren K, Watson DL, Morein B (1990) Effect of iscom and/or their adjuvant moiety (matrix) on the initial proliferative and il-2 responses in vitro. Comparison of spleen cells from mice inoculated with ISCOMs and/or matrix. Cell Immunol 129:414–425

    Article  PubMed  CAS  Google Scholar 

  21. Lövgren K, Morein B (1988) The requirement of lipids for the formation of immunostimulating complexes (ISCOMs). Biotechnol Appl Biochem 10:161–172

    PubMed  Google Scholar 

  22. Weijer K, Pfauth A, van Herwijnen R, Jarrett O, Meloen RH, Tomee C, Osterhaus AD (1993) Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene. Vaccine 11:946–956

    Article  PubMed  CAS  Google Scholar 

  23. Voeten JT, Rimmelzwaan GF, Nieuwkoop NJ, Lövgren-Bengtsson K, Osterhaus AD (2000) Introduction of the haemagglutinin transmembrane region in the influenza virus matrix protein facilitates its incorporation into ISCOM and activation of specific CD8(+) cytotoxic T lymphocytes. Vaccine 19:514–522

    Article  PubMed  CAS  Google Scholar 

  24. Oyewumi MO, Kumar A, Cui Z (2010) Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 9:1095–1107

    Article  PubMed  CAS  Google Scholar 

  25. Chen HC, Sun B, Tran KK, Shen H (2011) Effects of particle size on toll-like receptor 9-mediated cytokine profiles. Biomaterials 32:1731–1737

    Article  PubMed  CAS  Google Scholar 

  26. Lövgren Bengtsson K, Sjölander A (1996) Adjuvant activities of ISCOMs and ISCOM matrix; two different formulations of Quillaja saponin and antigen. Vaccine 14:753–760

    Article  Google Scholar 

  27. Madhun AS, Haaheim LR, Nilsen MV, Cox RJ (2009) Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine 27:7367–7376

    Article  PubMed  CAS  Google Scholar 

  28. Cox RJ, Pedersen G, Madhun AS, Svindland S, Sævik M, Breakwell L et al (2011) Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 29:8049–8059

    Article  PubMed  CAS  Google Scholar 

  29. Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ (2011) Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respi Viruses 5:426–437

    Article  PubMed  CAS  Google Scholar 

  30. Sjölander A, Lövgren Bengtsson K, Morein B (1997) Kinetics, localization and cytokine profile of T cell responses to immune stimulating complexes (ISCOMs) containing human influenza virus envelope glycoproteins. Vaccine 15:1030–1038

    Article  PubMed  Google Scholar 

  31. Paillot R, Grimmett H, Elton D, Daly JM (2004) Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host. Vet Res 39:21

    Article  Google Scholar 

  32. Crouch CF, Daly J, Hannant D, Wilkins J, Francis MJ (2004) Immune responses and protective efficacy in ponies immunised with an equine influenza ISCOM vaccine containing an ‘American lineage’ H3N8 virus. Vaccine 23:418–425

    Article  PubMed  CAS  Google Scholar 

  33. Heldens JG, Pouwels HG, Derks CG, Van de Zande SM, Hoeijmakers MJ (2009) The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap. Vaccine 27:5530–5537

    Article  PubMed  CAS  Google Scholar 

  34. Heldens JG, Pouwels HG, Derks CG, Van de Zande SM, Hoeijmakers MJ (2010) Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix. Vaccine 28:6989–6996

    Article  PubMed  CAS  Google Scholar 

  35. Kamstrup S, San Martin R, Doberti A, Grande H, Dalsgaard K (2000) Preparation and characterisation of quillaja saponin with less heterogeneity than Quil-a. Vaccine 18:2244–2249

    Article  PubMed  CAS  Google Scholar 

  36. Cox JC, Sjölander A, Barr IG (1998) ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev 32:247–271

    Article  PubMed  Google Scholar 

  37. Johansson M, Lövgren-Bengtsson K (1999) ISCOMs with different quillaja saponin components differ in their immunomodulating activities. Vaccine 17:2894–2900

    Article  PubMed  CAS  Google Scholar 

  38. Lövgren Bengtsson K, Morein B, Osterhaus AD (2011) ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines 10:401–403

    Article  PubMed  Google Scholar 

  39. Eyles JE, Hartley MG, Laws TR, Oyston PC, Griffin KF, Titball RW (2008) Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS). Microb Pathog 44:164–168

    Article  PubMed  CAS  Google Scholar 

  40. Douagi I, Forsell MN, Sundling C, O’Dell S, Feng Y, Dosenovic P et al (2010) Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates. J Virol 84:1683–1695

    Article  PubMed  CAS  Google Scholar 

  41. Dasari V, Smith C, Zhong J, Scott G, Rawlinson W, Khanna R (2011) Recombinant glycoprotein B vaccine formulation with toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus. J Gen Virol 92:1021–1031

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CSO, Isconova AB, Kungsgatan 109, SE-753 18, Uppsala, Sweden

    Karin Lövgren Bengtsson

Authors
  1. Karin Lövgren Bengtsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karin Lövgren Bengtsson .

Editor information

Editors and Affiliations

  1. Novartis Vaccines Research, Cambridge, 02139, Massachusetts, USA

    Manmohan Singh

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bengtsson, K.L. (2013). Matrix M Adjuvant Technology. In: Singh, M. (eds) Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-5380-2_15

Download citation

Publish with us

Policies and ethics

Search

Navigation